Fundamental Analysis of NOVABAY PHARMACEUTICALS INC(NYSEARCA:NBY) stock

Fundamental Rating

NBY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of NBY have multiple concerns. While showing a medium growth rate, NBY is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

NBY had negative earnings in the past year.

NBY had a negative operating cash flow in the past year.

In the past 5 years NBY always reported negative net income.

NBY had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -410.39%, NBY is doing worse than 94.27% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-410.39%
ROE	N/A
ROIC	N/A

ROA(3y)-103.8%

ROA(5y)-95.46%

ROE(3y)-240.85%

ROE(5y)-378.72%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of NBY (58.54%) is better than 65.63% of its industry peers.

NBY's Gross Margin has declined in the last couple of years.

NBY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	58.54%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-3.69%

GM growth 5Y-9.44%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NBY does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for NBY has been reduced compared to 1 year ago.

Compared to 5 years ago, NBY has less shares outstanding

Compared to 1 year ago, NBY has a worse debt to assets ratio.

2.2 Solvency

NBY has an Altman-Z score of -64.92. This is a bad value and indicates that NBY is not financially healthy and even has some risk of bankruptcy.

NBY's Altman-Z score of -64.92 is on the low side compared to the rest of the industry. NBY is outperformed by 94.79% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-64.92

ROIC/WACCN/A

WACC14.66%

2.3 Liquidity

A Current Ratio of 0.62 indicates that NBY may have some problems paying its short term obligations.

NBY has a worse Current ratio (0.62) than 93.75% of its industry peers.

NBY has a Quick Ratio of 0.62. This is a bad value and indicates that NBY is not financially healthy enough and could expect problems in meeting its short term obligations.

NBY has a worse Quick ratio (0.43) than 94.79% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.62
Quick Ratio	0.43

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NBY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.81%, which is quite impressive.

Looking at the last year, NBY shows a small growth in Revenue. The Revenue has grown by 2.26% in the last year.

The Revenue has been growing slightly by 3.32% on average over the past years.

EPS 1Y (TTM)41.81%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%95.37%

Revenue 1Y (TTM)2.26%

Revenue growth 3Y14.04%

Revenue growth 5Y3.32%

Sales Q2Q%-25.27%

3.2 Future

NBY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.92% yearly.

NBY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.24% yearly.

EPS Next Y98.72%

EPS Next 2Y41.15%

EPS Next 3Y25.92%

EPS Next 5YN/A

Revenue Next Year-25.07%

Revenue Next 2Y-2.82%

Revenue Next 3Y3.24%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NBY. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBY. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as NBY's earnings are expected to grow with 25.92% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.15%

EPS Next 3Y25.92%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NBY!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NOVABAY PHARMACEUTICALS INC

NYSEARCA:NBY (11/15/2024, 8:04:00 PM)

After market: 0.6803 -0.03 (-4.56%)

0.7128

-0.01 (-1.95%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap3.49M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-410.39%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	58.54%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover3.06

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.62
Quick Ratio	0.43
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)41.81%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y98.72%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)2.26%

Revenue growth 3Y14.04%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

NOVABAY PHARMACEUTICALS INC (NBY)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens